Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?

This article was originally published in PharmAsia News

Executive Summary

A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
Advertisement

Related Content

As Global Payers Become Monopolies, Biopharma Need To Demonstrate Value Earlier – AusBiotech Conference
Will More Subsidies For New Drugs Be A Core Promise Of New Australian Government?
What Impact Will Sept. 7 Australian Election Have On Pharma Industry?
Medicines Australia Lays Down Challenge On New PBS Listings For Next Government As September Polls Loom
Medicines Australia Says PBS Reforms Are Keeping Drug Prices Lower
Boehringer Ingelheim's Open Letter For Pradaxa Brings Australian PBS Back Into Spotlight
Pricing And Commercial Strategies For Emerging Markets Need To Be Built Into Drug Development Programs Early - DIA Conference
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
Australia Has Cheapest Drugs Compared To OECD Countries, UK Says
Advertisement
UsernamePublicRestriction

Register

SC078131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel